Allen Investment Management Has Raised Microsoft (MSFT) Holding; Proteostasis Therapeutics (PTI) Shorts Down By 5.18%

January 16, 2018 - By reb123z

Proteostasis Therapeutics Incorporated (NASDAQ:PTI) had a decrease of 5.18% in short interest. PTI’s SI was 495,600 shares in January as released by FINRA. Its down 5.18% from 522,700 shares previously. With 271,400 avg volume, 2 days are for Proteostasis Therapeutics Incorporated (NASDAQ:PTI)’s short sellers to cover PTI’s short positions. The SI to Proteostasis Therapeutics Incorporated’s float is 3.95%. The stock decreased 8.09% or $0.4075 during the last trading session, reaching $4.6325. About 435,786 shares traded. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has declined 66.87% since January 16, 2017 and is downtrending. It has underperformed by 83.57% the S&P500.

Allen Investment Management Llc increased Microsoft Corp (MSFT) stake by 9.55% reported in 2017Q3 SEC filing. Allen Investment Management Llc acquired 94,401 shares as Microsoft Corp (MSFT)’s stock rose 4.75%. The Allen Investment Management Llc holds 1.08 million shares with $80.65 million value, up from 988,254 last quarter. Microsoft Corp now has $693.77B valuation. The stock increased 0.37% or $0.33 during the last trading session, reaching $89.93. About 11.69 million shares traded. Microsoft Corporation (NASDAQ:MSFT) has risen 34.52% since January 16, 2017 and is uptrending. It has outperformed by 17.82% the S&P500.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $153.40 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

Investors sentiment increased to 0.83 in 2017 Q3. Its up 0.01, from 0.82 in 2017Q2. It improved, as 40 investors sold MSFT shares while 952 reduced holdings. 114 funds opened positions while 708 raised stakes. 5.51 billion shares or 0.32% less from 5.53 billion shares in 2017Q2 were reported. Caledonia Investments Public Limited Company has invested 14.45% in Microsoft Corporation (NASDAQ:MSFT). Athena Cap Advsrs Ltd owns 110,145 shares. Cardinal Cap Management invested 2.19% in Microsoft Corporation (NASDAQ:MSFT). Oarsman Cap holds 45,702 shares. Moreover, Blb&B Advsr Limited Liability has 1.99% invested in Microsoft Corporation (NASDAQ:MSFT) for 173,106 shares. Ims Cap reported 18,828 shares. 180,974 were accumulated by Northstar Investment Lc. Cibc Bancorporation Usa owns 61,789 shares for 0.6% of their portfolio. Private Advisor Gru Llc invested in 356,324 shares or 0.67% of the stock. Forte Cap Ltd Liability Company Adv owns 13,855 shares. Breton Hill Ltd reported 0.27% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Horizon Kinetics Limited Liability invested in 0.04% or 20,234 shares. Nexus Investment Management has invested 4.9% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Ascend Capital Ltd Com holds 402,388 shares or 1.13% of its portfolio. Oberweis Asset Management Inc holds 0.11% or 5,090 shares in its portfolio.

Allen Investment Management Llc decreased Alibaba Group Hldg Ltd (NYSE:BABA) stake by 2,491 shares to 21,027 valued at $3.63M in 2017Q3. It also reduced Alphabet Inc stake by 3,878 shares and now owns 19,167 shares. Tortoise Mlp Fd Inc (NTG) was reduced too.

Among 35 analysts covering Microsoft Corporation (NASDAQ:MSFT), 29 have Buy rating, 2 Sell and 4 Hold. Therefore 83% are positive. Microsoft Corporation had 143 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Microsoft Corporation (NASDAQ:MSFT) earned “Outperform” rating by Credit Suisse on Monday, July 17. The stock of Microsoft Corporation (NASDAQ:MSFT) earned “Overweight” rating by Morgan Stanley on Wednesday, January 13. The firm earned “Buy” rating on Monday, November 23 by UBS. The rating was maintained by Cowen & Co with “Market Perform” on Friday, April 1. As per Friday, October 21, the company rating was maintained by UBS. The company was maintained on Friday, August 28 by Global Equities Research. The stock of Microsoft Corporation (NASDAQ:MSFT) earned “Buy” rating by Raymond James on Friday, July 21. The company was maintained on Wednesday, November 15 by Bernstein. As per Tuesday, August 22, the company rating was maintained by Jefferies. The company was maintained on Wednesday, July 20 by BMO Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: